DURHAM, N.C.--(BUSINESS WIRE)--Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today financial results for the third quarter ended September 30, 2007, reporting a 26% increase in third quarter revenues as compared to 2006 and a net loss of $13.7 million, or ($0.32) per share. In August 2007, Inspire launched AzaSite™ (azithromycin ophthalmic solution) 1% in the United States for the treatment of bacterial conjunctivitis.
